Neuronopathy
Conditions
Keywords
neuronopathy, antibodies, Clinical and biological diagnostic criteria
Brief summary
The diagnosis of sensory neuronopathy is difficult to establish because the only certainty criterion is based on the detection of specific lesions in the posterior spinal ganglion which is usually not possible. There is to date no clinical and electrophysiological criteria or validated biomarker for the diagnosis of this type of neuropathy. In a retrospective study, we analyzed the files of patients with peripheral sensory neuronopathy certain and established clinical and electrophysiological diagnostic criteria for sensitive neuronopathy. We therefore wish now validate these criteria and investigate possible associated antibodies on a prospective cohort of patients.
Detailed description
All the patients (patient group and control) will be included in the study after giving their consent. The clinical, biological and electrophysiological data concerning the neuropathy will be collected. There is no specific follow-up for the study. Blood samples will be retrospectively analyzed for antibody screening.
Interventions
Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
Sponsors
Centre Hospitalier Universitaire de Saint Etienne
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A :Patients Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy. B :Controls Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
Exclusion criteria
* Patient with a sensory-motor neuropathy or incomplete clinical evaluation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Likelihood ratio diagnostic criteria established on the study population | baseline | The set of diagnostic criteria giving the best sensitivity and specificity for a diagnosis of sensory neuronopathy (composite measure) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identified antibodies | baseline | Sensibility and specificity of identified antibodies (composite measure) |
Countries
France
Outcome results
None listed